Venous Thromboembolism News and Research

RSS

High-risk patients not receiving recommended treatment for blood clots

Venous thromboembolism (VTE), encompassing deep-vein thrombosis (DVT), or blood clots in leg veins, and pulmonary embolism (PE), or clots that travel to the lungs, is the most common cause of preventable death in hospital settings. While these clots can be prevented by an approach called VTE prophylaxis, and this reduces mortality by as much as 80%, VTE prophylaxis is not universally prescribed for high-risk patients.

10 Aug 2015

More people turn to popular new blood thinners for atrial fibrillation treatment

More adults than ever are visiting their doctors' offices for a prescription to treat atrial fibrillation, according to a study led by the University of Michigan Frankel Cardiovascular Center.

23 Jul 2015

New UTMB study finds no association between testosterone therapy and blood clots in veins

A new study from The University of Texas Medical Branch at Galveston of more than 30,000 commercially insured men is the first large comparative analysis to show that there is no link between testosterone therapy and blood clots in veins. The study found that middle-aged and older men who receive testosterone therapy are not at increased risk of this illness.

21 Jul 2015

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.

13 Jul 2015

Findings could help improve patient care, reduce cancer screening costs around the world

A large clinical trial led by researchers at The Ottawa Hospital and the University of Ottawa has found that contrary to expectations, a CT scan of the abdomen and pelvis does not improve cancer detection in people with unexplained blood clots in their legs and lungs.

23 Jun 2015

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022" the Heparin Market Europe was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022.

17 Jun 2015

Study examines mental health prognosis of young VTE patients

EuroHeartCare is the official annual meeting of the Council on Cardiovascular Nursing and Allied Professions of the European Society of Cardiology. The 2015 meeting is held 14 to 15 June in Dubrovnik, Croatia, in collaboration with the Croatian Association of Cardiology Nurses.

15 Jun 2015

Data from statewide quality collaborative helps surgeons to reduce rates of serious trauma complication

As health insurers place more emphasis on paying for quality outcomes rather than for specific services provided by doctors and hospitals, several quality improvement programs have been developed as a way to help health care providers identify problem areas and share best practices. While some studies have evaluated how well these quality improvement programs achieve their goals, not many have focused on the area of trauma care.

11 Jun 2015

Newer anticoagulant medication may increase risk of GI bleeding in older patients

In a study released online in April in the BMJ, a team of researchers from Mayo Clinic, and other collaborators, showed that for older patients, particularly individuals greater than 75 years of age, the risk of gastrointestinal (GI) bleeding is 3 to 5 times higher when taking newer anticoagulant medications dabigatran or rivaroxaban compared to when using warfarin.

30 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Teens with slower cognitive processing speed experience depression, anxiety symptoms as adults

Teens with slower performance on a test of "cognitive processing speed" are more likely to have depression and anxiety symptoms as adults, reports a paper in Psychosomatic Medicine: Journal of Biobehavioral Medicine, the official journal of the American Psychosomatic Society.

20 May 2015

Lung cancer surgery patients at higher risk of developing venous thromboembolism

New evidence suggests that lung cancer surgery patients are at higher risk of developing venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), than previously thought, with elevated risks of complications or death. When thromboemboli occur, they may be asymptomatic or attributed to post-surgical pain or complications, and may reflect both the lung cancer itself as well as compromised lung function after surgery.

29 Apr 2015

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism.

16 Mar 2015

Post-mastectomy breast reconstruction does not increase complications in older women

Older women don't have an increased overall risk of complications from breast reconstruction after mastectomy, reports the February issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

2 Feb 2015

Steroid use associated with five-fold increase of blood clots in IBD patients

Compared with biologic therapy, corticosteroid (steroid) use is associated with a nearly five-fold increase of venous thromboembolism in inflammatory bowel disease (IBD) patients, according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Jan 2015

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).

8 Jan 2015

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients.

8 Dec 2014

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].

8 Dec 2014

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation.

24 Nov 2014

Three Johns Hopkins hospitals recognized as Top Performer on Key Quality Measures

Three Johns Hopkins Medicine hospitals are recipients of The Joint Commission’s 2013 Top Performer on Key Quality Measures award. The Top Performer program recognizes hospitals for improving performance on evidence-based interventions that increase the chances of healthy outcomes for patients with certain conditions, including heart attack, heart failure, pneumonia, surgical care, children’s asthma, stroke, venous thromboembolism (VTE) and perinatal care, as well as for inpatient psychiatric services and immunizations.

17 Nov 2014

Venous Thromboembolism News and Research

High-risk patients not receiving recommended treatment for blood clots

More people turn to popular new blood thinners for atrial fibrillation treatment

New UTMB study finds no association between testosterone therapy and blood clots in veins

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Findings could help improve patient care, reduce cancer screening costs around the world

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

Study examines mental health prognosis of young VTE patients

Data from statewide quality collaborative helps surgeons to reduce rates of serious trauma complication

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Teens with slower cognitive processing speed experience depression, anxiety symptoms as adults

Lung cancer surgery patients at higher risk of developing venous thromboembolism

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Post-mastectomy breast reconstruction does not increase complications in older women

Steroid use associated with five-fold increase of blood clots in IBD patients

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Three Johns Hopkins hospitals recognized as Top Performer on Key Quality Measures

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News